Search patients...
EL

Dr. Lee

Endocrinology

AR

Alex Rivera

Week 1 active

38Female · 5'5" · Tirzepatide · Week 1

Open Dose Review

Start weight

212 lbs

Current weight

209.8 lbs

Weight lost

-2.2 lbs

Current dose

2.5 mg · 25u

Adherence

1/1 doses

Patient Timeline

Intake completed

Health questionnaire submitted

Plan reviewed

Micro-titration plan shared

Week 1 injection

2.5 mg · 25 units administered

Week 1 check-in

Mild nausea 1/3 · improving

Week 2 approved

3.0 mg · 30 units approved

Prescription

MedicationTirzepatide
Concentration10 mg/mL
Syringe100u insulin
BMI35.3 kg/m²

Weight Trend (lbs)

Nausea Score (0–3)

Risk Profile

Intake-derived clinical flags

Response Accelerators

Hungry gut pattern

Persistent hunger despite meals

Emotional eating

Stress/emotion-triggered eating

Large meal capacity

Caution Factors

Reflux history

Prior GERD increases GI risk

Orthostatic risk

Muscle strength concern

Slow metabolizer

Algorithm rationale

Alex tolerated Week 1 with mild nausea only. No reflux, dizziness, or injection issues. Weight trending down (-2.2 lb). A 0.5 mg increase to 3.0 mg is recommended — smaller than standard protocol — to maintain momentum with lower GI risk.